The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03044743
Recruitment Status : Unknown
Verified April 2017 by Yang Yang, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.
Recruitment status was:  Recruiting
First Posted : February 7, 2017
Last Update Posted : May 2, 2017
Sponsor:
Information provided by (Responsible Party):
Yang Yang, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.

Condition or disease Intervention/treatment Phase
Stage IV Gastric Carcinoma Stage IV Nasopharyngeal Carcinoma T-Cell Lymphoma Stage IV Stage IV Adult Hodgkin Lymphoma Stage IV Diffuse Large B-Cell Lymphoma Drug: Fludarabine Drug: Cyclophosphamide Drug: Interleukin-2 Phase 1 Phase 2

Detailed Description:
This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin. Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response are evaluated. Biomarkers and immunological markers are also monitored.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies
Actual Study Start Date : April 7, 2017
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Fludarabine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PD-1 knockout EBV-CTL

Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).

Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.

A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.

Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment.

 Drug: Fludarabine
To modify immune micro-environment
Other Name: Fludara

Drug: Cyclophosphamide
To modify immune micro-environment
Other Name: Cytoxan

Drug: Interleukin-2
To sustain the survival of infused T cells
Other Name: IL-2


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: 90 days ]
  2. Progression free survival (PFS) [ Time Frame: up to 1 year ]
  3. Overall Survival (OS) [ Time Frame: up to 3 years ]
  4. The duration of the normalization of tumor marker [ Time Frame: up to 3 years ]
  5. Interferon-γ change of T cells in the peripheral blood stimulated by tumor antigens [ Time Frame: Baseline and 1 month, 3 months and 6 months ]
  6. Th1/Th2 change in the peripheral blood [ Time Frame: Baseline and 1 month, 3 months and 6 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically verified stage IV gastric carcinoma, nasopharyngeal carcinoma and lymphoma with measurable lesions (At least one measurable lesion or the immunotherapy)
  • Pathologically verified as EBV positive malignancies
  • Human leukocyte antigen (HLA) genotypes: HLA-A02, HLA-A24 or HLA-A11 genotypes
  • Progressed after standard treatment or the patients refused to accept the standard treatment
  • Performance score: 0-1
  • Expected life span: >= 3 months
  • Toxicities from prior treatment has resolved. Washout period is 1 months
  • Major organs function normally
  • Women at pregnant ages should be under contraception
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Patients with possible drug allergy of immunotherapy
  • Patients with active bacterial or fungal infections
  • Coagulopathy, or ongoing thrombolytics and/or anticoagulation
  • Blood-borne infectious disease, e.g. hepatitis B, hepatitis C and HIV
  • History of coronary artery disease, asthma, or vascular disease or other disease inappropriate for treatment deemed by treating physician
  • With other tumors except for in situ cervical cancer, treated squamous cell carcinoma and bladder cancer (Ta and TIS) or other malignancies that have been treated with radical therapy (at least for 5 years before the enrollment)
  • With other immune diseases, or chronic use of immunosuppressants or steroids
  • Pregnant and lactating women
  • Compliance cannot be expected
  • Other conditions requiring exclusion deemed by physician
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03044743


Contacts
Layout table for location contacts
Contact: Baorui Liu, MD 0086-25-83106666-61331 baoruiliu07@163.com
Contact: Shu Su, MD 0086-25-83106666-61331 ssnine@126.com

Locations
Layout table for location information
China, Jiangsu
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Recruiting
Nanjing, Jiangsu, China, 210008
Contact: Yang Yang, MD,PhD,MSCR    0086-18602568379    wing_young7@hotmail.com   
Contact: Jing Yan, MD    0086-15805182426    firefreebird@163.com   
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital Recruiting
Nanjing, Jiangsu, China, 210008
Contact: Yang Yang    18602568379    wing_young7@hotmail.com   
Sponsors and Collaborators
Yang Yang
Investigators
Layout table for investigator information
Principal Investigator: Baorui Liu, MD The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
ClinicalTrials.gov Identifier: NCT03044743    
Other Study ID Numbers: PD-1-KO-EBV-CTL
First Posted: February 7, 2017    Key Record Dates
Last Update Posted: May 2, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yang Yang, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School:
PD-1
CRISPR Cas9
EBV
advanced stage malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Carcinoma
Neoplasms
Hodgkin Disease
Lymphoma, Large B-Cell, Diffuse
Nasopharyngeal Carcinoma
Stomach Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Glandular and Epithelial
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
 Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Cyclophosphamide